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Abstract Since the late 1990s and early 2000s, derivatives
of well-known designer drugs as well as new psychoactive
compounds have been sold on the illicit drug market and
have led to intoxications and fatalities. The LC-MS/MS
screening method presented covers 31 new designer drugs
as well as cathinone, methcathinone, phencyclidine, and
ketamine which were included to complete the screening
spectrum. All but the last two are modified molecular
structures of amphetamine, tryptamine, or piperazine.
Among the amphetamine derivatives are cathinone, meth-
cathinone, 3,4-DMA, 2,5-DMA, DOB, DOET, DOM,
ethylamphetamine, MDDMA, 4-MTA, PMA, PMMA,
3,4,5-TMA, TMA-6 and members of the 2C group: 2C-
B, 2C-D, 2C-H, 2C-I, 2C-P, 2C-T-2, 2C-T-4, and 2C-T-7.
AMT, DPT, DiPT, MiPT, DMT, and 5MeO-DMT are
contained in the tryptamine group, BZP, MDBP, TFMPP,
mCPP, and MeOPP in the piperazine group. Using an
Applied Biosystems LC-MS/MS API 365 TurboIonSpray
it is possible to identify all 35 substances. After addition of
internal standards and mixed-mode solid-phase extraction
the analytes are separated using a Synergi Polar RP
column and gradient elution with 1 mM ammonium
formate and methanol/0.1% formic acid as mobile phases
A and B. Data acquisition is performed in MRM mode
with positive electro spray ionization. The assay is
selective for all tested substances. Limits of detection
were determined by analyzing S/N-ratios and are between
1.0 and 5.0 ng/mL. Matrix effects lie between 65% and
118%, extraction efficiencies range from 72% to 90%.
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Introduction
The term designer drugs stands for either synthetically
changed natural substances or completely designed molec-
ular structures that have psychotropic effects. Long known
and relatively widely used designer drugs are amphetamine,
methamphetamine, MDMA, MDEA, MDA, and MBDB
which can be regarded as the classical representatives and
are under control of international laws for a long time.
It is in the nature of these laws which are to ban psy-
chotropic substances to provoke the synthesis of new
derivatives. To bypass illegality, minor changes of common
molecular structures are sufficient—at least for some time.
Besides, basic structures are modified in order to optimize
effects. Since the late 1990s and early 2000s, modifications
of “classical” designer drugs have been sold as recreational
drugs or “research chemicals” on the black market.
As far as there is a demand, a continuing search and
introduction of new synthetic substances is to be assumed.
According to the World Drug Report 2008 of the United
Nations [1] the abuse of “other drugs”, including sub-
stances such as methaqualone, khat, LSD, ketamine, and
various new designer drugs, account for 3% of all drug
seizure cases. The situation in Germany is comparable as
the abuse remains on a very low level [2]. Nevertheless,
there have been several reports about intoxications and fatal
cases associated with the consumption of new designer
drugs [3–12]. For diagnosis of such poisonings, an
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analytical method for detection and quantification is
therefore required in clinical and forensic toxicology.
The substances that belong to “new designer drugs” can
be divided in five structural subgroups: phenylalkylamines
(mainly amphetamines), tryptamines, piperazines, pyrroli-
dinophenone, and phenylcyclohexyl derivates.
In the last years, several screening and validated quantifi-
cation methods using different techniques have been devel-
oped and published. However, generally, the focus lies on one
compound class or concentrates on a mix of frequently used
substances. For analysis of new designer amphetamines,
procedures were published using capillary electrophoresis—
mass spectrometry (CE-MS) for 2,5-methylendioxyamphet-
amines [13], the 2C-T-series [14], the ALEPH-series [15],
and 4-alkyl-2,5-dimethoxyamphetamines [16], using capil-
lary electrophoresis coupled with a diode array detector
(CE-DAD) for dimethoxyamphetamines [17] and liquid
chromatography–mass spectrometry (LC-MS) for the
TMA-series [18]. One method that mainly includes piper-
zines [19] and one for seven analytes of the 2C series [30]
use gas chromatography-mass spectrometry (GC-MS).
For analysis of mixtures GC-MS, LC-MS, and LC-MS/
MS procedures have been published, containing a compo-
sition of about six to ten new designer drugs from different
subgroups [20–23]. One GC-MS method for urine analysis
covered 16 substances [24].
As none of the above-mentioned methods going beyond
a limited number of analytes are applicable for serum or
covers more than one class, it was our intention to establish
an extensive LC-MS/MS screening method covering the
maximum number of available substances from all sub-
groups which can be detected in one run.
The LC-MS/MS screening method presented now includes
31 new designer drugs that could be purchased as reference
standards or were provided by the Landeskriminalamt Hamburg.
These substances are modified molecular structures of am-
phetamine, tryptamine, and piperazine. Pyrrolidinophenone or
phenylcyclohexyl derivates were not commercially available yet.
Cathinone and methcathinone which in fact are
amphetamine-like natural products as well as phencyclidine
and ketamine which have hallucinogenic effects were included
in the method because they also could be interesting for
designer drug consumers. Abbreviations are explained in
Table 1, an overview of substance classes and all new
designer drugs included in the method is given in Fig. 1.
Materials and methods
Chemicals and reagents
Methanolic solutions of 2,5-DMA, 2C-B, 2C-H, 2C-I, 2C-
T-2, 2C-T-4, 2C-T-7, 3,4,5-TMA, 3,4-DMA, 4-MTA,
benzylpiperazine, cathinone, DMT, DOB, DOET, DOM,
mCPP, MDDMA, methcathinone, N-ethylamphetamine,
phencyclidine, PMA, and PMMA as well as the internal
standards d5-amphetamine, d5-MDMA, d5-MDEA, and
d3-cocaine were obtained from Lipomed (Bad Säckingen,
Germany). MDBP, MeOPP, and DMPP were purchased
from Alfa Aesar (Karlsruhe, Germany). Methanolic sol-
utions of ketamine and of the internal standards d10-
fenfluramine, d5-phencyclidine, and d4-ketamine were
obtained from LGC Standards (Wesel, Germany). 2C-D,
2C-P, 5MeO-DMT, AMT, DiPT, DPT, MiPT, TFMPP, and
TMA-6 were kind gifts from the Landeskriminalamt
Hamburg, Germany.
Methanol (HPLC grade) was obtained from J.T. Baker
(Deventer, The Netherlands), dichloromethane and formic
acid (both analytical grade) from Roth (Karlsruhe, Ger-
many), ammonia (>25%), potassium dihydrogen phosphate,
and acetic acid (analytical grade) from Merck (Darmstadt,
Germany). Propan-2-ol (p.a.) was obtained from VWR
Prolabo (Briare, France) and ammonium formate from
Sigma-Aldrich (Steinheim, Germany).
Chromabond Drug cartridges (200 mg; 3 mL) for solid-
phase extraction were purchased from Macherey-Nagel
(Düren, Germany).
Preparation of stock solutions, working solutions,
calibration standards, and quality control samples
Stock solutions (1.0 mg/mL) of solid reference standards
were prepared using methanol as solvent and stored at
−20 °C. Stock solutions were then diluted with methanol to
obtain appropriate working concentrations (10 µg/mL,
1 µg/mL, and 100 ng/mL). Moreover, a mixture of the 35
analytes in methanol was prepared at the same concentra-
tion levels as the working solutions to facilitate the spiking
of samples later.
The internal standard solution contained 10 µg/mL of
d10-fenfluramine and d5-phencyclidine, and 5 µg/mL of
d5-amphetamine, d5-MDMA, d5-MDEA, d4-ketamine, d3-
cocaine, and dimethylphenylpiperazine, respectively.
Human blank plasma from drug free volunteers served
as matrix for standards and was spiked with the mixture of
the 35 analytes.
Extraction procedure
Plasma samples (1 mL) were spiked with 20 µL of internal
standard solution. The samples were then diluted with
phosphate buffer (pH 6), mixed on a rotary shaker and
loaded on solid-phase cartridges (Chromabond Drug)
previously conditioned with methanol and adjusted with
phosphate buffer at pH 6. Solid-phase extraction was
carried out on a Gilson GX-274 Aspec (Middleton, USA).
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After three washing steps (water, 1 mL, flow rate 2 mL/
min; acetic acid, 1 mL, flow rate 2 mL/min; methanol,
1 mL, flow rate 2 mL/min) the analytes were eluted with
1.5 mL of dichloromethane/isopropanol/25% ammonia
(80:20:2; v/v/v). The eluate was evaporated under a gentle
stream of nitrogen at 30 °C. During this evaporation step, a
mixture of concentrated hydrochloric acid and 2-propanol
(3:1, v/v) was added to prevent the volatile amphetamines
from vanishing. When dry, the residue was redissolved in
60 µL mobile phase and 20 µL was injected in the LC-MS/
MS system.
Apparatus
The LC system consisted of three Shimadzu AD 10 VP
pumps including a degasser (ERC-3415α), column oven
(Shimadzu CTO-10 AC) which was set at 40 °C and CTC
PAL autosampler and was controlled by a Shimadzu SCL-
10AVP. The chromatographic column was a Synergi Polar
RP column (150 mm×2 mm internal diameter, 4 µm,
Phenomenex) with a corresponding guard column (Polar
RP 4 mm×2.0 mm) which was kept on a constant
temperature of 40 °C.
As a detector, a Sciex API 365 tandem mass spectrom-
eter was used. It was equipped with an atmospheric
pressure electrospray ionization interface (Turboionspray®)
and run with Analyst software (version 1.3.1).
LC and MS conditions
The analytes were separated by gradient elution at a flow
rate of 0.25 mL/min, using 1 mM ammonium formate/0.1%
formic acid as mobile phase A and methanol/0.1% formic
acid as mobile phase B. Before use, the LC system was
2,5-DMA 1-(2,5-dimethoxyphenyl)propan-2-amine
2C-B 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine
2C-D 2-(2,5-dimethoxy-4-methylphenyl)ethanamine
2C-H 2-(2,5-dimethoxyphenyl)ethanamine
2C-I 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine
2C-P 2-(2,5-dimethoxy-4-propylphenyl)ethanamine
2C-T-2 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine
2C-T-4 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine
2C-T-7 2-[2,5-dimethoxy-4-(propylthio)phenyl]ethanamine
3,4,5-TMA 1-(3,4,5-trimethoxyphenyl)propan-2-amine
3,4-DMA 1-(3,4-dimethoxyphenyl)propan-2-amine
4-MTA 1-[4-(methylthio)phenyl]propan-2-amine
5MeO-DMT 2-(1H-indol-5-methoxy-3-yl)-N,N-dimethylethanamine
AMT 1-(1H-indol-3-yl)propan-2-amine
BZP 1-benzylpiperazine
DiPT 2-(1H-indol-3-yl)-N,N-diisopropylethanamine
DMPP (IS) 1-(3,4-dimethylphenyl)piperazine
DMT 2-(1H-indol-3-yl)-N,N-dimethylethanamine
DOB 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine
DOET 1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine
DOM 1-(2,5-dimethoxy-4-methylphenyl)propan-2-amine
DPT 2-(1H-indol-3-yl)-N,N-dipropylethanamine
Ethylamphetamine N-ethyl-1-phenylpropan-2-amine
mCPP 1-(3-chlorophenyl)piperazine
MDBP 1-(1,3-benzodioxol-5-ylmethyl)piperazine
MDDMA 1-(1,3-benzodioxol-5-yl)-N,N-dimethylpropan-2-amine
MeOPP 1-(4-methoxyphenyl)piperazine
MiPT 2-(1H-indol-3-yl)-N-isopropyl, N-methylethanamine
PMA 1-(4-methoxyphenyl)propan-2-amine
PMMA 1-(4-methoxyphenyl)-N-methylpropan-2-amine
TFMPP 1-[3-(trifluoromethyl)phenyl]piperazine
TMA-6 1-(2,4,6-trimethoxyphenyl)propan-2-amine
Table 1 Abbreviations
LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum 2405
equilibrated with a mixture of 90% mobile phase A and
10% mobile phase B. The gradient was as follows: from the
beginning the percentage of the organic phase B increased
continuously and reached 100% after 10 min. After that, the
column was cleaned with 100% mobile phase B for 3 min.
Reequilibration with 10% B took 2 min. Isopropanol was
added post-column with a constant flow rate of 0.2 mL/min.
During use, the mobile phases were degassed by the
integrated degasser.
Data acquisition was performed in MRM mode with
positive electrospray ionization.
The ESI inlet conditions were as follows: nebulizer gas,
nitrogen (10); curtain gas, nitrogen (11); ion spray voltage,
5,250 V; ion source temperature, 400 °C.
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Fig. 1 Classes of designer drugs and their chemical structures
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The MS setting was as follows: declustering potential,
10 V; focusing potential, 230 V; entrance potential, 10 V;
collision gas, nitrogen (2.8×10−5 torr); collision cell exit
potential, 15 V.
Proof of selectivity
In selectivity experiments, plasma samples from different
persons were checked for interfering peaks in MRM tran-
sitions of analytes as well as internal standards. Furthermore,
two zero samples that were only spiked with internal standard
solution were tested for undeuterated traces of deuterated
substances that might pretend the presence of analytes.
Analytes themselves can also show interfering signals in
MRM transitions which might pretend the presence of other
analytes or wrongly increase their quantity. That is why we
monitored single analyte solutions of 1 µg/ml for additional
peaks.
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Fig. 1 (continued)
LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum 2407
Limits of detection
According to the validation guideline of the German
Society of Toxicological and Forensic Chemistry for
calculation of limits of detection (LOD) blank plasma
samples of the local blood bank (1 mL) were spiked with
working solutions to obtain calibration standards with
concentrations of 1.0, 2.5, 5.0, 7.5, and 10.0 ng/mL. They
were worked up and analyzed as described above.
Six neat samples with 50 ng of all analytes in mobile
phase served for determination of relative ion intensities.
Extraction efficiencies and matrix effects
As proposed by Matuszewski et al. [25], extraction
efficiencies and matrix effects were calculated using three
different sets of samples.
Bearing in mind that the highest limit of detection was
10 ng/mL, we decided to work with a concentration of
50 ng/mL to certainly achieve a signal-noise-ratio greater
than 10 and exceed the limit of quantification.
The samples of Set 1 consisted of neat standards
containing the analytes. Fifty microliters of the designer
drug mixture (c=1µg/mL), 20 µl of internal standard
solution, and 100 µl of hydrochloric acid/2-propanol (1:3,
v/v) were mixed and evaporated to dryness. The residue
was redissolved in 60 µL mobile phase.
For preparation of Set 2 blank plasma samples from five
volunteers (1 mL, each) plus 70 µl of methanol were extracted
by the above-mentioned solid-phase extraction method. After
that, the eluate was spiked with 50 µL of the same designer
drug mixture and 20 µl of internal standard solution and was
evaporated. Before the residue was completely dry, 100 µl of
hydrochloric acid/2-propanol were added to prevent the
amphetamines from volatilizing. Again, the dry residue was
reconstituted in 60 µl mobile phase.
Samples of Set 3 were prepared like usual quality control
samples. Blank plasma samples from the same five volunteers as
for Set 2were spikedwith 50 µL designer drugmix and 20 µL of
internal standard mix. Solid-phase extraction followed. The
eluatewas then evaporated to dryness (again by using the organic
hydrochloric acid mixture) and redissolved in mobile phase.
Tryptamines 
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Fig. 1 (continued)
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Matrix effects can be estimated by comparison of the
peak areas of Set 1 and Set 2. Extraction efficiencies are
calculated by comparison of the peak areas of Set 2 and 3.
Mean values and standard deviations of matrix effects as
well as extraction efficiencies are reported in percentage
and are listed in Table 2.
Results and discussion
A screening method was developed for selective detection
of 31 new designer drugs containing amphetamine, trypt-
amine, and piperazine structures in human plasma.
In the course of method development, the evaporation
turned out to be the weak point of the extraction process. It is
well-known that amphetamine volatilizes rapidly during
evaporation, some amphetamine derivatives happened to act
likewise. To limit the evaporation of analytes, the evaporation
process the addition of hydrochloric acid in organic solvent,
such as isopropanol, prior to evaporation of the extracts was
applied.
In the beginning, product ion scans at collision energies
of 20, 35, and 50 eV using a 10 µg/mL standard solution of
each analyte in methanol were carried out to determine the
most intense fragments. Three spectra of each analyte have
been collected and were added in our LC-MS/MS library
data base as described in [26] along with their compound
names, CAS numbers, formulas, and molecular weights.
Finally, two or three MRM transitions were chosen which
were not further optimized.
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Fig. 1 (continued)
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One transition is monitored for the internal standards
whereas the majority of drugs is detected by using two
MRM transitions. In cases of isobaric compounds three
MRM transitions are used. Often, these substances show
nearly the same MS/MS spectra. If no alternative, suffi-
ciently intensive transitions existed identical transitions
had to be monitored. Consequently, retention time and
relative ion intensities definitely have to be considered for
identification.
Substances with identical precursor masses in Q1 are:
– 4-MTA and 2C-H, m/z 182
– 2,5-DMA, 2C-D and 3,4-DMA, m/z 196
– 2C-P and DOET, m/z 224
– 3,4,5-TMA and TMA-6, m/z 226
– DiPT and DPT, m/z 245
– 2C-T-4 and 2C-T-7, m/z 256
To obtain acceptable cycle times, the general dwell time
for the analytes was set at 15 and 20 ms for internal
standards. To improve intensity or peak shape, the dwell
time was extended to 40 ms for benzylpiperazine, MDBP,
phencyclidine, cathinone, and methcathinone. Eventually,
the method includes 91 transitions and has a cycle time of
2.17 s.
As can be seen in Fig. 2, some very similar substances
(2C-T-4/2C-T-7, DiPT/DPT as well as 2C-P/DOET) could
not be completely baseline separated. Nevertheless, they are
No Substance name Extraction efficiency (mean ± SD, %) Matrix effect (mean ± SD, %)
1 Cathinone 83±17.3 99±3.1
2 Ethylamphetamine 74±16.3 99±10.1
3 Methcathinone 81±18.3 84±6.1
4 PMA 80±17.7 118±6.8
5 AMT 79±19.2 103±5.3
6 BZP 72±22.0 65±9.3
7 PMMA 84±12.6 91±3.6
8 2C-H 79±13.4 97±6.1
9 4-MTA 84±19.8 98±18.0
10 DMT 81±12.7 83±19.4
11 MeOPP 90±27.5 85±15.3
12 2,5-DMA 86±13.7 100±7.2
13 2C-D 80±16.8 99±6.3
14 3,4-DMA 84±10.1 98±5.9
15 mCPP 77±17.0 93±7.3
16 MDDMA 76±11.5 92±2.5
17 DOM 75±24.7 106±8.5
18 MiPT 77±9.4 100±5.9
19 5MeO-DMT 79±7.3 105±9.6
20 MDBP 76±16.4* 67±17.8
21 2C-P 73±14.0 98±2.9
22 DOET 81±18.3 93±6.7
23 3,4,5-TMA 76±23.1 106±11.4
24 TMA- 6 79±15.0 110±11.7
25 TFMPP 78±25.7 98±6,8
26 ketamine 89±18.7 85±7.3
27 2C-T-2 79±14.2 106±8.0
28 phencyclidine 72±14.5 90±5.7
29 DiPT 82±13.0 94±2.6
30 DPT 78±19.6 99±7.4
31 2C-T-4 74±24.8 107±5.0
32 2C-T-7 72±17.3 102±7.8
33 2C-B 79±19.2 99±7,4
34 DOB 86±16.9 93±2.4
35 2C-I 76±14.1 102±3.6
Table 2 Extraction efficiency
and matrix effect for the
studied analytes
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distinguishable without difficulty by their different reten-
tion times and different relative ion intensities.
The inclusion of internal standards covering the whole
runtime and compound classes is very helpful to evaluate
retention times when they tend to vary. Comparing
retention times of analyte and its corresponding internal
standard compensates time shifts.
An overview about the selected transitions of the
analytes as well as their corresponding collision energies,
retention times, and relative ion intensities is given in
Table 3. Product ion scan spectra which were recorded
during development are published on the website of
ChemicalSoft [27].
The method was found to be selective for all tested
analytes. Selectivity experiments with nine different plasma
samples revealed neither interferences of matrix com-
pounds, metabolites, or impurities nor undeuterated traces
in deuterated internal standards.
Analytes themselves did not show any interfering
signals.
As criteria of identification, a signal-to-noise-ratio of
greater than or equal to 3 in at least two transitions was set
according to international accepted recommendations.
Furthermore, relative ion intensities had to be within the
given limits in the EU guideline 2002/657 [28]. According
to this guideline, the allowed deviations of relative ion
intensities are as follows:
– Relative ion intensity (in percent) of the first qualifier
under 10%: ±50%
– Relative ion intensity (in %) of the first qualifier 10–
20%: ±30%
– Relative ion intensity (in %) of the first qualifier 20–
50%: ±25%
– Relative ion intensity (in %) of the first qualifier more
than 50%: ±20%
At the given limits of detection, all the analytes fulfilled
these criteria.
Limits of detection were between 1.0 and 5.0 ng/mL and
are listed in Table 3 with the signal-to-noise-ratios of the
quantifier and the first qualifier.
As there is only little experience with new designer
drugs, data on “therapeutic” and toxic serum concentrations
is rare. For some substances, first hints are given by case
reports already published: in fatal cases, plasma concen-
trations for BZP were 0.71, <0.50, and 1.39 mg/L, for
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Fig. 2 Smoothed chromatogram of a serum sample spiked with all analytes in a concentration of 50 ng/mL and internal standard solution after
solid-phase extraction. The numbers correspond to the numbers in Table 3
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Table 3 MRM transitions and corresponding collision energies, retention times, relative ion intensity of the first qualifier related to the target,
corresponding internal standard and limits of detection of all substances
No Substance name Q1
mass
(amu)
Q3
mass
(amu)
Collision
energy
(eV)
tR(min) Relative ion
intensity
qualifier/target
Internal
standard
LOD
(ng/ml)
S/N ratio
quantifier
S/N ratio
qualifier
1 Cathinone 150.0 132.1 20 4.21 70% d5-amphetamine 2.5 22 28
117.1 35
2 Ethylamphetamine 164.0 91.0 35 5.79 35% d5-MDMA 2.5 17 5
119.0 20
3 Methcathinone 164.0 146.1 20 4.57 41% d5-amphetamine 1.0 19 8
131.1 20
4 PMA 166.0 121.1 20 5.37 86% d5-MDMA 1.0 5 4
149.1 20
5 AMT 175.0 158.2 20 5.57 33% d5-MDMA 2.5 23 5
143.1 35
6 BZP 177.0 91.1 35 2.91 12% d5-amphetamine 5.0 56 5
65.1 50
7 PMMA 180.0 149.1 20 5.74 81% d5-MDMA 1.0 19 21
121.1 35
8 2C-H 182.0 165.2 20 5.63 64% d5-MDMA 1.0 40 6
150.1 20
135.2 35
9 4-MTA 182.0 165.2 20 6.66 57% d4-ketamine 2.5 15 17
117.1 20
137.2 35
10 DMT 189.0 58.1 20 5.46 85% d5-MDMA 2.5 14 8
144.1 20
11 MeOPP 193.0 150.1 20 5.36 61% d5-MDMA 2.5 13 4
119.0 35
12 2,5-DMA 196.0 151.1 20 6.14 72% d5-MDEA 5.0 15 12
179.2 20
121.1 35
13 2C-D 196.0 179.2 20 6.63 24% d4-ketamine 1.0 6 8
149.1 35
164.2 20
14 3,4-DMA 196.0 179.1 20 5.03 49% d5-amphetamine 1.0 5 5
151.1 20
107.1 50
15 mCPP 197.0 154.1 50 6.69 82% DMPP (IS) 1.0 14 4
118.1 35
16 MDDMA 208.0 163.2 20 5.97 32% d5-MDEA 1.0 7 9
105.1 35
17 DOM 210.0 193.2 20 7.00 46% d10-fenfluramine 1.0 10 14
165.2 20
18 MiPT 217.0 86.2 20 6.46 71% d4-ketamine 2.5 19 4
144.2 35
19 5MeO-DMT 219.0 174.2 20 5.64 63% d5-MDMA 1.0 8 6
58.2 35
20 MDBP 221.0 135.1 20 3.33 11% d5-amphetamine 5.0 49 4
76.9 50
21 2C-P 224.0 207.2 20 8.00 33% d5-PCP 1.0 18 57
192.2 20
163.3 35
22 DOET 224.0 207.1 20 7.71 19% d3-cocaine 5.0 209 17
177.1 35
192.2 20
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TFMPP 0.05 and 0.15 mg/L [5], for 2C-T-7 0.057 mg/L (in
heart blood) [29], for 4-MTA 4.6 mg/L (in femoral blood)
[10], for DOB 0.019 mg/L [7], and for PMA 0.24–4.9 mg/L
(six fatalities) [11]. In a nonfatal case of mCPP intoxication,
the plasma concentration was 0.32 mg/L [3], in another case
of a DOB ingestion, the concentration was 0.013 mg/L,
marginally lower than in the fatal case [7].
Regarding these values, it is safe to assume that serum
concentrations will exceed the limits of detection.
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Table 3 (continued)
No Substance name Q1
mass
(amu)
Q3
mass
(amu)
Collision
energy
(eV)
tR(min) Relative ion
intensity
qualifier/target
Internal
standard
LOD
(ng/ml)
S/N ratio
quantifier
S/N ratio
qualifier
23 3,4,5-TMA 226.0 209.1 20 5.32 10% d5-MDMA 2.5 5 4
181.1 20
194.1 20
24 TMA- 6 226.0 209.2 20 6.95 21% d10-fenfluramine 2.5 15 7
181.2 35
121.2 35
25 TFMPP 231.0 188.2 35 6.99 15% DMPP (IS) 5.0 141 28
118.1 50
26 ketamine 238.0 125.0 35 6.51 83% d4-ketamine 2.5 7 10
220.2 20
27 2C-T-2 242.0 225.2 20 7.35 7% d3-cocaine 1.0 19 8
210.2 35
28 phencyclidine 244.0 86.1 20 8.23 90% d5-PCP 2.5 9 14
159.1 50
29 DiPT 245.0 114.2 20 7.35 97% d3-cocaine 1.0 42 15
144.1 35
117.1 50
30 DPT 245.0 114.2 20 7.60 49% d3-cocaine 1.0 10 9
144.2 35
86.2 35
31 2C-T-4 256.0 239.2 20 7.72 29% d3-cocaine 1.0 20 4
167.2 35
182.1 20
32 2C-T-7 256.0 239.2 20 7.98 9% d5-PCP 1.0 11 8
167.2 35
182.1 35
33 2C-B 260.0 243.1 20 7.01 27% d10-fenfluramine 2.5 53 15
228.1 35
34 DOB 274.0 257.0 20 7.34 45% d3-cocaine 1.0 7 5
229.1 20
35 2C-I 308.0 291.0 20 7.45 28% d3-cocaine 1.0 55 12
276.0 35
36 d5-amphetamine 141.0 93.1 20 4.74
37 dimethylphenylpiperazine 191.0 133.1 35 6.78
38 d5-MDMA 199.0 165.1 20 5.68
39 d5-MDEA 213.0 163.2 20 6.13
40 d4-ketamine 242.0 129.0 35 6.46
41 d10-fenfluramine 243.0 161.2 20 7.06
42 d3-cocaine 307.0 185.2 20 7.11
43 d5-phencyclidine 249.0 164.2 20 8.21
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